Tags

Type your tag names separated by a space and hit enter

An update on medication management of behavioral disorders in autism.
Curr Psychiatry Rep. 2014 Mar; 16(3):437.CP

Abstract

Autism spectrum disorder is often comorbid with behavioral disturbances such as irritability, aggression and hyperactivity. Throughout the mid 2000s, several large-scale controlled clinical trials were published leading to the approval of two medications (aripiprazole and risperidone) for treatment of irritability in this condition. This review serves as an update regarding new research findings regarding psychopharmacology for children and adolescents with ASD. In summary, the past five years have yielded no further approved medications with ASD as a primary indication. Important new research results include 1) long-term safety and efficacy data (52 week) regarding treatment with aripiprazole for irritability, 2) consensus regarding potential harm from SSRIs for treatment of repetitive behaviors in children/ adolescents with ASD, 3) a randomized controlled trial showing modest benefits from atomoxetine on hyperactivity, 4) many novel agents currently under investigation.

Authors+Show Affiliations

Department of Psychiatry, University of Toronto, Toronto, ON, Canada.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24488702

Citation

Baribeau, Danielle A., and Evdokia Anagnostou. "An Update On Medication Management of Behavioral Disorders in Autism." Current Psychiatry Reports, vol. 16, no. 3, 2014, p. 437.
Baribeau DA, Anagnostou E. An update on medication management of behavioral disorders in autism. Curr Psychiatry Rep. 2014;16(3):437.
Baribeau, D. A., & Anagnostou, E. (2014). An update on medication management of behavioral disorders in autism. Current Psychiatry Reports, 16(3), 437. https://doi.org/10.1007/s11920-014-0437-0
Baribeau DA, Anagnostou E. An Update On Medication Management of Behavioral Disorders in Autism. Curr Psychiatry Rep. 2014;16(3):437. PubMed PMID: 24488702.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An update on medication management of behavioral disorders in autism. AU - Baribeau,Danielle A, AU - Anagnostou,Evdokia, PY - 2014/2/4/entrez PY - 2014/2/4/pubmed PY - 2014/10/1/medline SP - 437 EP - 437 JF - Current psychiatry reports JO - Curr Psychiatry Rep VL - 16 IS - 3 N2 - Autism spectrum disorder is often comorbid with behavioral disturbances such as irritability, aggression and hyperactivity. Throughout the mid 2000s, several large-scale controlled clinical trials were published leading to the approval of two medications (aripiprazole and risperidone) for treatment of irritability in this condition. This review serves as an update regarding new research findings regarding psychopharmacology for children and adolescents with ASD. In summary, the past five years have yielded no further approved medications with ASD as a primary indication. Important new research results include 1) long-term safety and efficacy data (52 week) regarding treatment with aripiprazole for irritability, 2) consensus regarding potential harm from SSRIs for treatment of repetitive behaviors in children/ adolescents with ASD, 3) a randomized controlled trial showing modest benefits from atomoxetine on hyperactivity, 4) many novel agents currently under investigation. SN - 1535-1645 UR - https://www.unboundmedicine.com/medline/citation/24488702/An_update_on_medication_management_of_behavioral_disorders_in_autism_ L2 - https://dx.doi.org/10.1007/s11920-014-0437-0 DB - PRIME DP - Unbound Medicine ER -